Literature DB >> 18715780

Helicobacter species are associated with possible increase in risk of hepatobiliary tract cancers.

Manoj Pandey1, Mridula Shukla.   

Abstract

BACKGROUND: Attempts at early identification of hepatobiliary cancers have failed due to non-availability of a sensitive test. Prevention offers the best chance to reduce the morbidity and mortality from these. Identification of an etiological agent and especially if the potentially identified cause can be eradicated like Helicobacter sp. infection, will not only reduce incidence but also the mortality.
METHODS: This article reviews 15 studies on Helicobacter species in hepatobiliary cancers identified on pubmed, scopus and google scholar search. Of these, Five were single group and 10 were case control. These 10 case control studies were included in the meta analysis, which was carried out using odds ratio and both a fixed and random effect model, 95% confidence intervals for odds ratio was calculated. Chi square test for heterogeneity was employed. The overall effect was calculated using Z test.
RESULTS: The cumulative sample size of cases was 205, of which 115 were positive (56%) for Helicobacter, while among 263 controls 53 (20%) were found to be positive for Helicobacter infection. The positivity rate in case control studies was higher than that observed in single group studies. The cumulative odds ratio for the study sample was 8.72 (95% CI 4.78-15.91) (Z=7.07; p<0.00001).
CONCLUSIONS: There is enough evidence to suggest a possible role of Helicobacter species in hepatobiliary tract cancers. However, the results from different regions of the world differ. Studies also differ on method of Helicobacter detection, subsite of cancer with in the hepatobiliary tract and choice of controls thus introducing heterogeneity. Further case control studies with larger sample size are required to settle the question.

Entities:  

Mesh:

Year:  2008        PMID: 18715780     DOI: 10.1016/j.suronc.2008.07.002

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  7 in total

Review 1.  Association between Helicobacter spp. infections and hepatobiliary malignancies: a review.

Authors:  Fany Karina Segura-López; Alfredo Güitrón-Cantú; Javier Torres
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

2.  Lipopolysaccharide-pathway proteins are associated with gallbladder cancer among adults in Shanghai, China with mediation by systemic inflammation.

Authors:  Alison L Van Dyke; Troy J Kemp; Amanda F Corbel; Bin Zhu; Yu-Tang Gao; Bing-Sheng Wang; Asif Rashid; Ming-Chang Shen; Allan Hildesheim; Ann W Hsing; Ligia A Pinto; Jill Koshiol
Journal:  Ann Epidemiol       Date:  2016-08-31       Impact factor: 3.797

3.  Helicobacter pylori in gallbladder mucosa in patients with gallbladder disease.

Authors:  Virinder Kumar Bansal; Mahesh C Misra; Gaurav Chaubal; S Datta Gupta; Bimal Das; Vineet Ahuja; Sushma Sagar
Journal:  Indian J Gastroenterol       Date:  2012-02-21

Review 4.  From the stomach to other organs: Helicobacter pylori and the liver.

Authors:  Marek Waluga; Michał Kukla; Michał Żorniak; Agata Bacik; Rafał Kotulski
Journal:  World J Hepatol       Date:  2015-08-28

5.  Medical risk factors associated with cholangiocarcinoma in Taiwan: a population-based case-control study.

Authors:  Jeffrey S Chang; Chia-Rung Tsai; Li-Tzong Chen
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

Review 6.  New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin.

Authors:  Maria Consiglia Bragazzi; Lorenzo Ridola; Samira Safarikia; Sabina Di Matteo; Daniele Costantini; Lorenzo Nevi; Vincenzo Cardinale
Journal:  Ann Gastroenterol       Date:  2017-11-02

7.  Helicobacter pylori is not a contributing factor in gallbladder polyps or gallstones: a case-control matching study of Chinese individuals.

Authors:  Jinshun Zhang; Ying Zhang; Yahong Chen; Weiling Chen; Hongfang Xu; Wei Sun
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.